A carregar...
Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAF(V600E) Melanoma
Acquired clinical resistance to vemurafenib, a selective BRAF(V600E) inhibitor, arises frequently after short term chemotherapy. Since inhibitions of targets in the RAF-MEK-ERK pathway result in G(0)/G(1) cell cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell cycle ar...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3947172/ https://ncbi.nlm.nih.gov/pubmed/24249714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0212 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|